Fragment-Based Screening

Fragment-based screening is a drug discovery approach that involves screening small, low-molecular-weight chemical fragments (typically 150-300 Da) against a biological target to identify weak binders. These fragments are then optimized through medicinal chemistry into potent lead compounds. It is widely used in pharmaceutical and biotech industries to develop novel therapeutics, particularly for challenging targets like protein-protein interactions.

Also known as: FBS, Fragment-Based Drug Discovery, FBDD, Fragment Screening, Fragment-Based Lead Discovery

Why learn Fragment-Based Screening?

Developers should learn this methodology if working in computational chemistry, bioinformatics, or drug discovery software, as it requires tools for molecular docking, virtual screening, and data analysis. It is essential for roles involving structure-based drug design, where integrating fragment libraries with structural biology data (e.g., from X-ray crystallography or NMR) accelerates lead identification. Use cases include developing algorithms for fragment scoring, building databases of fragment libraries, or creating visualization tools for fragment binding modes.

Learning Resources

• docs: Fragment-Based Drug Discovery: A Practical Introduction
• course: Fragment-Based Screening in Drug Discovery - Coursera Course
• video: Introduction to Fragment-Based Drug Design - YouTube Tutorial
• book: Fragment-Based Drug Discovery: Methods and Protocols (Book)